Page 38 - கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
April 21, 2021 07:00 ET | Source: Khondrion Khondrion
Study will examine of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study (NCT04846036) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
Sonlicromanol, Khondrion’s wholly-owned, investigational lead asset, is currently being tested in a Phase IIb study as a potentially disease-modifying treatment for adults with mitochondrial disease. The compound is a
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol .
KhondrionApril 21, 2021 GMT
Study will examine
of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study ( NCT04846036 ) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
ADVERTISEMENT
Tel: +44 (0) 20 7597 5970 Daniel Adams / Gary Clarence / Patrick Robb AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand
®, RESORBA
®, and LiquiBandFix8
®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal
® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 202
vimarsana © 2020. All Rights Reserved.